Sellas Life Sciences: A $2.2 Billion Bet on a Leukemia Trial’s Final Two Events
Published on 07/13/2026 at 16:36 | Redaktion boerse-global.de
The numbers are excruciatingly close. Sellas Life Sciences needs 80 deaths in its phase 3 REGAL study to trigger the final data analysis. As of May 11, it had logged 78. Two missing events separate the biotech from a make-or-break verdict on its lead asset, Galinpepimut-S (GPS), an immunotherapy for acute myeloid leukemia. The clock is ticking toward a binary outcome that will either validate a 570% rally or wipe out most of those gains.
Investors have already priced in a lot of hope. The stock hit a 52-week low of €1.22 in November 2025; today it changes hands around €11.35, giving the company a market capitalisation of roughly €2.2 billion. The ascent has been fuelled by a cocktail of clinical tension, speculative chatter about a Merck & Co. takeover, and a violent short squeeze. Nearly one-third of the free float — 31.43% — was sold short as of late May, a bet against the stock that has backfired spectacularly as the trial nears its endpoint. The combination of limited supply and heavy bearish positioning can send a low-float name parabolic, and Sellas has been no exception.
Merck looms over the story for a concrete reason. The pharma giant’s blockbuster cancer drug Keytruda generated $31.7 billion in revenue last year, accounting for 55% of corporate drug sales. But its US patent protection expires in 2028, creating an urgent need to replenish the pipeline. GPS targets the WT1 protein, a well-validated tumour antigen, and a positive REGAL readout would open a clear regulatory path to the FDA — making Sellas an obvious acquisition candidate. Nothing has been confirmed, but the logic is compelling enough to keep retail traders dreaming.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
On the clinical front, Sellas remains blinded to the results. The study compares GPS maintenance therapy to a control arm, and statistical success requires a median overall survival of at least 12.6 months versus eight months in the placebo group. The fact that the final two events are taking time could be interpreted as a bullish signal: patients may simply be living longer, delaying the count. Still, the company does not expect the final analysis before the second half of 2026, possibly late in the third quarter or even the fourth.
Beyond REGAL, Sellas is advancing its CDK9 inhibitor SLS009 (Tambiciclib) through a phase 2 study in newly diagnosed AML patients as a first-line therapy. The first patient was dosed in the first quarter of 2026, and a primary completion date is set for the end of the year. The company also has a cash runway that should bridge the gap: $107.1 million in hand as of March 31, supplemented by a $150 million equity facility. That is enough to reach the REGAL readout without diluting shareholders at distressed prices — unless the trial fails, in which case the financing picture would shift dramatically.
Volatility remains extreme. The annualised figure stands at roughly 124%, reflecting the nervous anticipation around a single data point. On a 30-day view the stock is up 64%, yet the past seven trading sessions have shaved off 7.4% — a reminder that the rally is anything but smooth. The relative strength index sits at 59.4, a neutral zone that suggests neither overbought nor oversold conditions. Technical signals such as widening Bollinger Bands and the emergence of a potential death cross imply that the easy momentum may be fading and profit-taking could accelerate.
Analysts at Maxim Group remain bullish, with a consensus price target of €15.33 — roughly 35% above current levels. But targets are only as good as the underlying probability. Until those final two events arrive, Sellas is trading not on fundamentals but on a probability distribution with a binary centre. The stock is a placeholder for a verdict that will come later this year. For holders who have ridden the 570% surge, the true test is still ahead.
Ad
Sellas Life Sciences Stock: New Analysis - 13 July
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
